emrosi
emrosi: developed by 2 companies · 1 FDA decision. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Journey Medical Corp (DERM) | Approved |
| Fortress Biotech Inc. (FBIO) | Approved |
FDA Decisions
Frequently asked questions
Who is developing emrosi?
emrosi is being developed by Journey Medical Corp, Fortress Biotech Inc..
What is emrosi's latest FDA decision?
The most recent tracked FDA decision for emrosi is Approval for 1 INDICATIONS AND USAGE EMROSI is indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults. Limitations of Use This formulation of minocycline has not been evaluated in the treatment or prevention of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, use EMROSI only as indicated. EMROSI is a tetracycline-class drug indicated to treat inflammatory lesions (papules and pustules) of rosac, dated November 1, 2024.
Get deeper analysis on emrosi
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis